TJ-M2010-5, a novel MyD88 inhibitor, corrects R848-induced lupus-like immune disorders of B cells in vitro.
Sign Up to like & getrecommendations! Published in 2020 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2020.106648
Abstract: B cell hyperactivities are involved in the development of systemic lupus erythematosus (SLE). Toll-like receptor 7 (TLR7) in the B cells plays a pivotal role in the pathogenesis of SLE. Previous studies have focused on… read more here.
Keywords: m2010 novel; lupus like; r848 induced; lupus ... See more keywords
The Novel MyD88 Inhibitor TJ-M2010-5 Protects Against Hepatic Ischemia-reperfusion Injury by Suppressing Pyroptosis in Mice
Sign Up to like & getrecommendations! Published in 2022 at "Transplantation"
DOI: 10.1097/tp.0000000000004317
Abstract: Background . With the development of medical technology and increased surgical experience, the number of patients receiving liver transplants has increased. However, restoration of liver function in patients is limited by the occurrence of hepatic… read more here.
Keywords: pyroptosis; hepatic iri; myd88 inhibitor;